Tils - OmicsDI

Show results for

Unknown (1949)
Genomics (415)
Transcriptomics (223)
Other (21)
Proteomics (20)
Methylation profiling (6)
Clinical (2)
Models (1)
Genomic (1)
Metabolomics (1)

Organisms

Homo sapiens (159)
Mus musculus (125)
Mycobacterium tuberculosis SP7 (17)
Mycobacterium tuberculosis SP10 (17)
Mycobacterium tuberculosis SP13 (17)
Mycobacterium tuberculosis SP22 (17)
Chlamydomonas reinhardtii (17)
Enterococcus mundtii CRL35 (17)
Oncorhynchus tshawytscha (17)
Pseudomonas canadensis (17)
Pseudomonas aeruginosa PAO1H2O (17)
Human alphaherpesvirus 1 strain 17 (17)
Mycobacterium tuberculosis SP1 (17)
Marchantia polymorpha subsp. ruderalis (17)
Methylocystis sp. (17)
Thermoplasma acidophilum DSM 1728 (1)
Arabidopsis thaliana (1)
Cytomegalovirus (1)
Rhadinovirus (1)
Lymphocryptovirus (1)
Merkel cell polyomavirus (1)
JC polyomavirus (1)
Betapolyomavirus hominis (1)
Human alphaherpesvirus 2 (1)
Betapolyomavirus macacae (1)
Human alphaherpesvirus 1 (1)
Murid gammaherpesvirus 4 (1)
Human betaherpesvirus 5 (1)
Human immunodeficiency virus 1 (1)
Rattus norvegicus (1)

Organisms

Mus musculus (163)
Homo sapiens (155)

Repository

ENA (383)
geo (243)
biostudies-arrayexpress (23)
pride (17)
EGA (16)
BioModels (1)
dbGaP (1)
iProX (1)
jPOST (1)
MassIVE (1)
MetaboLights (1)

Tissue

Epithelial cell (3)
T cell (3)
Epithelial ovarian cancer cell (2)
Ovarian serous carcinoma cell (2)
Spleen (2)
Acinar cell (1)
Follicular lymphoma cell (1)
Mucosal melanoma cell (1)
SW-620 cell (1)
MiaPaCa-2 cell (1)
Colorectal adenocarcinoma cell line (1)
B-lymphoblastoma cell (1)
Stromal cell (1)
T-lymphocyte cell line (1)
Pancreatic cancer cell line (1)
Breast epithelium (1)
Breast cancer cell (1)
Breast (1)
Pancreas (1)
Skin (1)
Brain (1)
Permanent cell line cell (1)
B cell (1)
Cell culture (1)

Disease

Breast cancer (3)
Malignant neoplasm of ovary (2)
Lung Neoplasms (1)
Colorectal Neoplasms (1)
Cutaneous malignant melanoma 1 (1)
Brain glioblastoma multiforme (1)
Ovarian serous carcinoma (1)
Pancreatic cancer (1)
Colon cancer (1)

Technology Type

Mass Spectrometry (17)
Shotgun proteomics (10)
Bottom-up proteomics (3)
Affinity purification coupled with mass spectrometry proteomics (2)
NextSeq 500, ILLUMINA (1)
Illumina HiSeq 2500, ILLUMINA (1)
ILLUMINA, Illumina HiSeq 2500 (1)
Illumina HiSeq 4000, Illumina HiSeq 2500, ILLUMINA (1)
Mass spectrometry (1)
SWATH MS (1)
Data-dependent acquisition (1)
Top-down proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (3)
DNBSEQ-T7 (2)
Agilent Technologies Scanner G2505C (1)
Illumina HiSeq 4000 (1)
LTQ Orbitrap Velos (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2025 (41)
2024 (39)
2023 (32)
2026 (31)
2021 (29)
2022 (28)
2020 (18)
2019 (15)
2016 (14)
2018 (10)
2017 (9)
2013 (6)
2009 (5)
2012 (4)
2015 (2)
2014 (2)
2007 (2)

UNIPROT ID/AC

O25420 (1)
Q48271 (1)
O25044 (1)
O25333 (1)
O25332 (1)
O25786 (1)
O25071 (1)
O25342 (1)
O26078 (1)
O26085 (1)
O26018 (1)
O25376 (1)
O25488 (1)
Q48262 (1)
O25014 (1)
O26011 (1)
O25838 (1)
O25551 (1)
O25150 (1)
O25011 (1)
O26077 (1)
O25505 (1)
P56003 (1)
O25122 (1)
O25124 (1)
P56117 (1)
P56176 (1)
O25872 (1)
O26103 (1)
O26102 (1)

CHEBI ID

CHEBI:190663 (1)
CHEBI:164781 (1)
CHEBI:159767 (1)
CHEBI:170052 (1)
CHEBI:194292 (1)
CHEBI:161812 (1)
CHEBI:158783 (1)
CHEBI:194290 (1)
CHEBI:194289 (1)
CHEBI:194284 (1)
CHEBI:194280 (1)
CHEBI:161337 (1)
CHEBI:194276 (1)
CHEBI:194264 (1)
CHEBI:68747 (1)
CHEBI:194277 (1)
CHEBI:194271 (1)
CHEBI:190673 (1)
CHEBI:194262 (1)
CHEBI:194255 (1)
CHEBI:194251 (1)
CHEBI:89100 (1)
CHEBI:194293 (1)
CHEBI:194254 (1)
CHEBI:194267 (1)
CHEBI:194288 (1)
CHEBI:194266 (1)
CHEBI:194252 (1)
CHEBI:194261 (1)
CHEBI:194294 (1)

Metabolite Name

ACar 24:2 (1)
4-(3-methyl-1-phenyl-1H-pyrazolo[3,4-b]quinolin-4-yl)morpholine (1)
N1-bicyclo[2.2.2]oct-2-ylbenzamide (1)
N1-(2-cyanoethyl)-3-amino-4-chlorobenzene-1-sulfonamide (1)
2-(4-hydroxy-1,3-thiazol-2-yl)-1-phenylethan-1-one (1)
LysoPC 16:2 (2N Isomer) (1)
5alpha-Pregnan-3,20-dione (1)
Ethyl 4-amino-2-[(3-nitro-2-pyridyl)thio]pyrimidine-5-carboxylate (1)
N-(4-fluorophenyl)-N'-[2-methyl-5-(piperidinosulfonyl)-3-furyl]urea (1)
2-[2-oxo-2-(pyridin-3-ylamino)ethoxy]acetic acid (1)
N-(4-chlorophenyl)-5-hex-1-ynylnicotinamide (1)
Methyl 6-[(4-chlorophenyl)thio]-5-nitronicotinate (1)
Evernic acid (1)
PC (20:1/20:2) (1)
-Estradiol (1)
11,12-DiHETE (1)
4-(2-furyl)-2-oxo-6-(2-thienyl)-1,2-dihydro-3-pyridinecarbonitrile (1)
-Aspartylphenylalanine (1)
L-Glutathione (oxidized) (1)
-Glutamylcysteine (1)
3'-Dephospho-CoA (1)
1-(2-pyridin-2-yldiazenyl)-2-naphthol (1)
(S)-Bromoenol lactone (1)
3-(allylsulfanyl)-4-[4-(benzyloxy)phenyl]-5-methyl-4H-1,2,4-triazole (1)
2-({2-[(5-methylisoxazol-3-yl)amino]-2-oxoethyl}thio)acetic acid (1)
2,6-dimethyl-4-(3-thienyl)pyridine-3,5-dicarboxylic acid (1)
7-methylpyrimido[4,5-d]pyrimidin-4-amine (1)
L-Cycloserine (1)
Alpha-Lapachone (1)
WMH (1)

First Public Date

2025 (69)
2026 (58)
2024 (51)
2021 (44)
2022 (43)
2023 (41)
2020 (22)
2019 (18)
2016 (11)
2018 (9)
2017 (8)
2014 (8)
2015 (1)

Modelling Approach

Constraint-based model (1)

Study status

Not provided (1)
Recruiting (1)

Lab affiliation

Director of Women’s Health Research Women’s Service Line Inova Health System (2)
Institute for Research in Biomedicine (IRB), Barcelona Institute of Science and Technology (BIST), Barcelona 08028, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona 08010, Spain (1)
Neuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, 8091 Zurich, Switzerland (1)
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Heilongjiang Cancer Institute, Harbin 150081, Heilongjiang Province, People闁炽儲鐛� Republic of China. (1)
Immunology and Radiation Oncology Moffitt Cancer Center Tampa, FL, USA (1)
Immunotherapy Program, Lineberger Comprehensive Cancer Center Department of Cell Biology & Physiology, University of North Carolina at Chapel Hill (1)
Professor, Head of Cancer Research, University of Southern Denmark (1)
Proteomics Service CIC bioGUNE Bizkaia Tech. Park Build. 800 48160 Derio Spain (1)
Università del Piemonte Orientale, Dipartimento di medicina traslazionale. (1)
Section/Core Facility Mass Spectrometry and Proteomics, University Medical Center Hamburg-Eppendorf (UKE), Martinistr. 52, 20246 Hamburg, Germany (1)
European Institute of Oncology (1)
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel (1)
Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Barcelona, Spain. (1)
Proteomics Service CIC bioGUNE Bizkaia Tech. Park Build. 800 Derio 48160 Spain (1)
Nuffield Department of Medicine, University of Oxford, OX3 7FZ, U.K. (1)
Mass Spectrometry Laboratory, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland (1)

Keyword

NT-I7 (Efineptakin alfa) (1)
Non-small Cell Lung (1)
Small Cell Lung (1)
Programmed cell death protein (PD-1) (1)
TIL (1)
Breast (1)
Thoracic Neoplasms (1)
Interleukin 7 (1)
Pancreas (1)
Lung (1)
Colorectal (1)
Ovarian (1)
Pembrolizumab (1)
Antibodies (1)
Immunotherapy (1)

IsPrivate

False (1)

Study type

Transcription profiling by array (15)
RNA-seq of coding RNA from single cells (4)
RNA-seq of coding RNA (4)
Interventional (2)

Release Date

2022 (298)
2021 (293)
2023 (251)
2025 (231)
2024 (190)
2020 (189)
2019 (136)
2018 (105)
2017 (80)
2016 (71)
2015 (34)
2026 (22)
2014 (20)
2013 (13)
2011 (10)
2012 (8)
2009 (6)
2007 (3)
2010 (3)
2006 (3)
2005 (2)
2008 (1)
2004 (1)
2002 (1)
1997 (1)

Location

China (1)
United States (1)

Previous page
1 / 264
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 264
Next page

Sort by:

Relevance

Page size

Gene expression differences between TILs that are reactive to tumor cells and TILs that are not reactive

PRJNA1060655 | ENA

RNA-seq of T in PBMC and TILs

PRJNA663398 | ENA

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Not available

S-EPMC6267863 | biostudies-literature

Transcriptomic profile of Traf6-deficient CD8+ TILs

PRJNA922497 | ENA

RNA-sequencing of melanoma-derived tumor-infiltrating lymphocytes (TILs)

PRJNA601330 | ENA

Gene expression signature of ex vivo expanded TILs for 14 day

PRJNA1169801 | ENA

Gene expression differences between TILs that are reactive to tumor cells and TILs that are not reactive

Clinical significance of tumor-infiltrating lymphocytes (TILs) was demonstrated in many tumor types. In the clinical trials, immune check point inhibitors showed significant clinical efficacy in some tumor types with high mutation burden such as melanoma, bladder cancer, and smoking-induced lung can...

ORGANISM(S): Homo sapiens

2025-06-30 | GSE252437 | GEO

Transcriptome differences in HCC infiltrated CD8+ T cells in effector and exhaustion state

CD8+ T cells isolated from HCC tissue were divided into three groups: PD1-TIM3- CD8+ TILs, exhibiting full effector function; PD1-intTIM3+ CD8+ TILs, exhibiting partial exhaustion; and PD1-hiTIM3+ CD8+ TILs, exhibiting severe exhaustion, as reflected by the differences in their ability to produce ef...

ORGANISM(S): Homo sapiens

2019-12-31 | E-MTAB-7278 | biostudies-arrayexpress

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.

Not available

S-EPMC5325445 | biostudies-literature

Expression data from FACS-sorted CD8+BTLA+ vs CD8+BTLA- Human Tumor-infiltrating Lymphocytes in Metastatic Melanoma

Adoptive T-cell Therapy (ACT) involves using tumor-infiltrating lymphocytes (TIL) isolated from metastatic melanoma and expanding them ex vivo prior to infusion into lympho-depleted patients. This is one of the most promising approaches to treat metastatic melanoma, with the rates of clinical respo...

ORGANISM(S): Homo sapiens

2013-01-03 | E-GEOD-43260 | biostudies-arrayexpress

Previous page
1 / 264
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 264
Next page

Sort by:

Relevance

Page size

2639 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets